Nonin Medical, Inc. announced today the publication of two separate studies that demonstrate the clinical efficacy of the company's EQUANOX™ Model 7600 Cerebral and Somatic Oximetry System in adult and pediatric patients. The studies, published in the Annals of Thoracic Surgery (November) and the Journal of Cardiothoracic and Vascular Anesthesia (December), demonstrate the clinical effectiveness of Nonin's EQUANOX sensors in measuring critical oxygen saturation levels in the brain. The studies are the first published results to demonstrate the absolute accuracy of a near infra-red spectroscopy (NIRS) cerebral oximeter system in a wide range of patients. Nonin Medical sponsored the studies.
The EQUANOX System is a NIRS-based monitoring device that noninvasively and continuously detects oxygen saturation status in the brain and other tissue. The device allows clinicians to quickly react to reverse harmful tissue ischemia events before they become critical.
"Nonin is pleased with the publication of these peer-reviewed studies validating the industry-leading absolute accuracy of the EQUANOX cerebral oximeter system," said Jill Wroblewski, Senior Manager of Market Development for Nonin Medical. Unlike other regional oximetry systems that may only indicate whether oxygen levels are increasing or decreasing, EQUANOX's proprietary technology provides real-time absolute accuracy of actual physiologic conditions on neonatal to adult patients, regardless of age, weight or skin color, for accuracy clinicians can trust and act on."
Advantages of the EQUANOX Advance Model 7600 Oximetry System include: